Highest-materiality recent filing
Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC
Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.
Black Diamond reports positive Phase 2 silevertinib results; mPFS 15.2 months in EGFR-NCM NSCLC
Preliminary mPFS 15.2 months (95% CI: 10.8, NE); median DOR not reached; 53% of patients remain on therapy.
Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026
Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
60% ORR (26/43) in 1L NSCLC with 35 distinct non-classical EGFR mutations; 86% CNS ORR in patients with brain metastases.
Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M
Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.
Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027
Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.
Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones
Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.
Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026
Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.
Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data
Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.
CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.
Black Diamond reports initial Phase 2 data for BDTX-1535 showing 42% ORR in recurrent EGFRm NSCLC
200 mg daily dose selected for pivotal development; favorable tolerability with no new safety signals.
Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track
Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.
Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024
Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.
22 evaluable patients: 3 on therapy >10 months, 1 >6 months, 5 >4 months; historical PFS is 2–4 months.
Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials
Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).
Black Diamond Therapeutics appoints Mark Velleca as CEO; David Epstein steps down
David M. Epstein separated as President and CEO effective Sept 15, 2023; remains on board until 2024 annual meeting.
Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity
Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.
Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share
Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.
BDTX-1535 shows 5/12 NSCLC patients with confirmed partial response; expansion cohorts planned
5 of 12 evaluable NSCLC patients achieved confirmed partial response per RECIST 1.1; 1 unconfirmed PR, 6 stable disease.
Black Diamond Q1 net loss $20.9M; cash $103.4M; BDTX-1535 update H2 2023; BDTX-4933 IND cleared
Cash $103.4M as of March 31, down from $122.8M at year-end 2022; net loss $20.9M vs $25.5M in Q1 2022.
Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023
Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).
Black Diamond Therapeutics spins out Launchpad Therapeutics with $30M Series A from Versant and NEA
Spinout of Launchpad, an antibody-focused precision oncology company; $30M Series A led by Versant Ventures and NEA.
Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024
Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.
Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024
Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.
Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed
Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).
Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).
Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024
Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.
Black Diamond submits IND for BDTX-1535 ahead of schedule; cash runway extended to 2024
IND submitted for BDTX-1535 (CNS-penetrant EGFR inhibitor) for GBM and NSCLC; Phase 1 expected Q1 2022 subject to FDA allowance.
Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022
FDA allowed IND application for BDTX-1535 on January 10, 2022.
Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO
CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.
Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end
Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.
Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing
Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.
Black Diamond appoints interim CMO and new CSO; CMO and CSO depart
Karsten Witt appointed Interim CMO, effective Aug 4, 2021, succeeding Rachel Humphrey.
Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.
On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024
Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board
the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director
Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).
Rajeev Shah notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position as a member of the Audit Committee of the Board, effective immediately.
The Board appointed Samarth Kulkarni, Ph.D. to serve as the Lead Independent Director of the Board
On September 18, 2023, Black Diamond Therapeutics, Inc. (the “Company”) announced that it separated with David M. Epstein, Ph.D. as President and Chief Executive Officer and principal executive officer of the Company, in each case, effective as of September 15, 2023
Effective September 16, 2023, the Board appointed Mark A. Velleca, M.D., Ph.D. as President and Chief Executive Officer and principal executive officer of the Company
On December 13, 2022, Robert A. Ingram notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position of Chairman of the Board
On December 15, 2022, upon the recommendation of the NCG Committee, the Board appointed current Board member Mark A. Velleca, M.D., Ph.D. to serve as Chairman of the Board.
On April 5, 2022, Brad Bolzon, Ph.D. notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.65 · Most common event earnings